Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kasper Iversen

Showing results (51-60 of 217) with videos related to

Pageof 22
Sort By:
Heart (British Cardiac Society)|December 15, 2015
Functional effects of losartan in hypertrophic cardiomyopathy-a randomised clinical trialAnna Axelsson, Kasper Iversen, Niels Vejlstrup, et al.
International Journal of Cardiology|November 3, 2012
Troponin T is a strong marker of mortality in hospitalized patientsKasper Iversen, Lars Køber, Jens Peter Gøtze, et al.
Annals of the American Thoracic Society|December 14, 2020
Alcohol Consumption and the Risk of Acute Respiratory Distress Syndrome in COVID-19Mats Christian Højbjerg Lassen, Kristoffer Grundtvig Skaarup, Morten Sengeløv, et al.
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|July 3, 2021
Danish citizens' preferences for at-home oropharyngeal/nasal SARS-CoV-2 specimen collectionJohan S Bundgaard, Daniel T Raaschou-Pedersen, Tobias Todsen, et al.
American Heart Journal|April 13, 2024
Patient characteristics, treatment patterns, and prognosis in drug-use-associated infective endocarditis in Denmark from 1999 to 2018Jeppe Kofoed Petersen, Lucas Grove Vejlstrup Bager, Lauge Østergaard, et al.
Journal of Cardiovascular Medicine (Hagerstown, Md.)|March 26, 2014
Atrioventricular conduction after alcohol septal ablation for obstructive hypertrophic cardiomyopathyAnna Axelsson, Kristina Weibring, Ole Havndrup, et al.
Open Forum Infectious Diseases|September 16, 2022
SARS-CoV-2 Surface Swabs in Locations With Public Access-Potential for Improved Source ControlJacob P S Nielsen, Johannes R Madsen, Kamille Fogh, et al.
Emergency Medicine Journal : EMJ|September 4, 2016
Soluble urokinase plasminogen activator receptor (suPAR) in acute care: a strong marker of disease presence and severity, readmission and mortality. A retrospective cohort studyLine Jee Hartmann Rasmussen, Steen Ladelund, Thomas Huneck Haupt, et al.
American Heart Journal|November 18, 2023
Angiotensin receptor blockers in patients with hypertrophic cardiomyopathy: A comparison of VANISH and INHERIT randomized trialsTino Severinsen, Jens Jakob Thune, Helga Lillian Gudmundsdottir, et al.
The Lancet. Diabetes & Endocrinology|December 24, 2014
Efficacy and safety of the angiotensin II receptor blocker losartan for hypertrophic cardiomyopathy: the INHERIT randomised, double-blind, placebo-controlled trialAnna Axelsson, Kasper Iversen, Niels Vejlstrup, et al.
Pageof 22

Showing results (51-60 of 217) with videos related to

Sort By:
Pageof 22
Heart (British Cardiac Society)|December 15, 2015
Functional effects of losartan in hypertrophic cardiomyopathy-a randomised clinical trialAnna Axelsson, Kasper Iversen, Niels Vejlstrup, et al.
International Journal of Cardiology|November 3, 2012
Troponin T is a strong marker of mortality in hospitalized patientsKasper Iversen, Lars Køber, Jens Peter Gøtze, et al.
Annals of the American Thoracic Society|December 14, 2020
Alcohol Consumption and the Risk of Acute Respiratory Distress Syndrome in COVID-19Mats Christian Højbjerg Lassen, Kristoffer Grundtvig Skaarup, Morten Sengeløv, et al.
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|July 3, 2021
Danish citizens' preferences for at-home oropharyngeal/nasal SARS-CoV-2 specimen collectionJohan S Bundgaard, Daniel T Raaschou-Pedersen, Tobias Todsen, et al.
American Heart Journal|April 13, 2024
Patient characteristics, treatment patterns, and prognosis in drug-use-associated infective endocarditis in Denmark from 1999 to 2018Jeppe Kofoed Petersen, Lucas Grove Vejlstrup Bager, Lauge Østergaard, et al.
Journal of Cardiovascular Medicine (Hagerstown, Md.)|March 26, 2014
Atrioventricular conduction after alcohol septal ablation for obstructive hypertrophic cardiomyopathyAnna Axelsson, Kristina Weibring, Ole Havndrup, et al.
Open Forum Infectious Diseases|September 16, 2022
SARS-CoV-2 Surface Swabs in Locations With Public Access-Potential for Improved Source ControlJacob P S Nielsen, Johannes R Madsen, Kamille Fogh, et al.
Emergency Medicine Journal : EMJ|September 4, 2016
Soluble urokinase plasminogen activator receptor (suPAR) in acute care: a strong marker of disease presence and severity, readmission and mortality. A retrospective cohort studyLine Jee Hartmann Rasmussen, Steen Ladelund, Thomas Huneck Haupt, et al.
American Heart Journal|November 18, 2023
Angiotensin receptor blockers in patients with hypertrophic cardiomyopathy: A comparison of VANISH and INHERIT randomized trialsTino Severinsen, Jens Jakob Thune, Helga Lillian Gudmundsdottir, et al.
The Lancet. Diabetes & Endocrinology|December 24, 2014
Efficacy and safety of the angiotensin II receptor blocker losartan for hypertrophic cardiomyopathy: the INHERIT randomised, double-blind, placebo-controlled trialAnna Axelsson, Kasper Iversen, Niels Vejlstrup, et al.
Pageof 22